Valcadia Healthcare Partners a leading healthcare investment banking and M&A advisory firm, announced that it has advised Carolina Urologic Cancer Center, the premier urologic clinical research site specializing in genitourinary oncology, in its acquisition by The START Center for Cancer Research, a global leader in early-phase oncology clinical trials. The transaction closed in April 2025 and represents Valcadia’s fourth completed outsourced pharma services transaction, a milestone which reflects the firm’s leadership in advising health sciences entrepreneurs and business owners.
Health Technology Insights: Rocket Doctor AI Partners to Boost AI Clinical Support in Alberta
Founded in 1998 by Neal Shore, MD, FACS, CURC has conducted nearly 500 clinical trials, making it the top urologic oncology site worldwide by both volume and quality. With deep expertise in early phase as well as late phase trials, CURC brings unparalleled leadership and scientific insight to START’s global research portfolio. With the integration of CURC’s specialized trial capabilities and expertise and to further strengthen its leadership in GU oncology research, START has established a dedicated Center of Excellence (COE) focused on delivering a comprehensive trial solution for urological cancers.
Health Technology Insights: Soleo Health Names Jody Thompson SVP of Rare Disease Business Development
“Joining START’s global site network marks an exciting new chapter for CURC,” said Dr. Neal Shore, Founder and Medical Director of CURC. “START is the leader in early phase oncology trials, and we share a mission to bring the hope of clinical trials to patients worldwide. I am honored to lead START’s GU Oncology growth as well as their commitment to radiopharmaceutical trial expansion.”
“Valcadia Healthcare Partners was essential in helping CURC identify the right strategic partner,” added Dr. Shore. “I strongly recommend Valcadia as they displayed unwavering professionalism, insight and diligence in guiding us through this successful transaction.”
“We are honored to have advised CURC through this pivotal partnership,” said Ethan Goodson, Founder and Managing Partner at Valcadia Healthcare Partners. “Dr. Shore and the entire CURC team have built a leading community-based urologic oncology research practice grounded in clinical excellence and strengthened by a mission-driven culture that permeates the entire organization. We are proud to have supported them in securing a partner that will preserve and build upon that identity, and we look forward to following their continued growth and success.”
Bass, Berry & Sims PLC provided legal counsel to CURC in connection with the transaction, and ReedSmith LLP provided legal counsel to START.
Health Technology Insights: Amphista Reveals AMX-883 Preclinical Data for AML Therapy
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
